Immunogenicity & Safety of SARS-CoV-2 Protein Subunit Recombinant Vaccine (Bio Farma) Adjuvanted With Alum+CpG 1018 Compared to Registered Covid-19 Vaccine (Covovax - Protein Subunit Vaccine) in Healthy Populations Aged 18 Years and Above in Indonesia (Phase III)
Latest Information Update: 30 Nov 2023
At a glance
- Drugs SARS CoV 2 vaccine-PT Bio Farma (Primary) ; COVID-19 vaccine adjuvanted Novavax
- Indications COVID 2019 infections
- Focus Pharmacodynamics; Registrational
- Sponsors PT Bio Farma
Most Recent Events
- 27 Nov 2023 Status changed from active, no longer recruiting to completed.
- 15 Sep 2022 Status changed from recruiting to active, no longer recruiting.
- 30 Jun 2022 New trial record